Last reviewed · How we verify
NCT03904927
Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma
Phase 2 trial testing Radiation, Surgery or Radiofrequency ablation in Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma in 104 participants. Completed in 15 September 2024.
1 January 2022
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 104 |
| Start date | 1 February 2019 |
| Primary completion | 1 January 2022 |
| Estimated completion | 15 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Radiation, Surgery or Radiofrequency ablation
- Systemic therapy — full drug profile →
Conditions studied
- Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma — all drugs for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to determine if intervening with combined local therapy and chemotherapy prior to chemotherapy alone in patients with oligorecurrent and oligometastatic esophageal squamous cell carcinoma led to significant improvements in progression-free survival (PFS).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial.
Liu Q, Chen J, Lin Y, Ye J, et al · · 2024 · cited 52× · PMID 37980921 · DOI 10.1016/s2468-1253(23)00316-3 -
Current status and perspectives of esophageal cancer: a comprehensive review.
Jiang W, Zhang B, Xu J, Xue L, et al · · 2025 · cited 28× · PMID 39723635 · DOI 10.1002/cac2.12645 -
Local therapy for oligometastatic esophageal squamous cell carcinoma: a prospective, randomized, Phase II clinical trial.
Liu Q, Chen J, Li B, Ye J, et al · · 2021 · cited 8× · PMID 33626929 · DOI 10.2217/fon-2020-0873 -
Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment.
Kroese TE, Bronzwaer SFC, van Hillegersberg R, van Rossum PSN, et al · · 2023 · cited 1× · PMID 41647727 · DOI 10.1016/j.esmogo.2023.08.008 -
The role of radiotherapy in small cell carcinoma of the esophagus: a retrospective study.
Yang H, Li Y, Ge H. · · 2025 · cited 1× · PMID 40390071 · DOI 10.1186/s13014-025-02662-3
Verify or expand the search:
- PubMed search for NCT03904927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03904927 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03904927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing